Nasus Pharma is trading at $3.56 (+11.25%), with the reason unconfirmed.
- No company-specific announcement, filing, earnings release, or analyst action was identified for August 14, 2026.
- Available coverage lists older developments, including the July 28 CEO appointment and June clinical updates, rather than a fresh catalyst.
- The broader market is lower, with major indexes declining, so the advance is not clearly explained by macro sentiment.